AM-Pharma publishes safety and pharmacokinetic data from Phase I recAP trial

Pharmacokinetic model determines optimal dose regimen for current Phase IIb recAP dose finding clinical study treating sepsis-associated acute kidney injury Bunnik, The Netherlands, 10 May 2016. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase), has published data from its Phase I trial of recAP, for the potential treatment […]

AM-Pharma receives FDA fast track designation for recAP in Acute Kidney Injury

AM-Pharma receives FDA fast track designation for recAP in Acute Kidney Injury, and reports completion of first stage in Phase II trial Trial on track and FDA regulatory status may allow accelerated patient access to new drug Bunnik, The Netherlands, 26 April 2016. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant […]

AM-Pharma STOP-AKI Phase II trial nominated for “Most Innovative Clinical Trial Design”

Bunnik, The Netherlands, 19 April 2016. AM-Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) has been shortlisted for the “Most Innovative Clinical Trial Design” in the inaugural Clinical & Research Excellence Awards in Boston, organised by Informa Business Intelligence (IBI). The nomination is based on AM-Pharma’s two-part adaptive […]

AM-Pharma and Pfizer Inc. shortlisted for “Best Partnership Alliance” in 2015 Scrip Awards

Bunnik, The Netherlands, 30 September 2015. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase), and Pfizer Inc. have been nominated for the prestigious category of “Best Partnership Alliance” for the 11th Annual Scrip Awards, organised by Scrip Intelligence, the leading source of news and strategic analysis for the […]

AM-Pharma publishes further preclinical data on recAP to treat Acute Kidney Injury

Two papers present mode of action and pharmacokinetic model for recAP Bunnik, The Netherlands, 30 September 2015. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase), today announces the publication of two papers on recAP for the potential treatment of Acute Kidney Injury (AKI). The first, published in the […]

AM-Pharma receives FDA and EMA orphan drug designation to treat hypophosphatasia

The orphan designations secure recAP position in rare disease area Bunnik, The Netherlands, 9 June 2015. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase), today announces that the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have both granted orphan designation status to recAP for […]

Pfizer Acquires Minority Interest in AM-Pharma; Secures Option to Acquire Company

Option may be exercised based on Phase II trial results for recombinant human Alkaline Phosphatase Bunnik, The Netherlands, and New York, NY – 11 May 2015 – AM‐Pharma B.V., a privately held Dutch biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP ) for inflammatory diseases, and Pfizer Inc. (NYSE: PFE) announced […]

AM-Pharma starts Adaptive Phase II trial of recAP in Acute Kidney Injury

Bunnik, The Netherlands, 20 January 2015. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory diseases, has recruited the first 3 patients into its Phase II trial of recAP in sepsis-associated Acute Kidney Injury (AKI). The clinical trial is now underway in 9 countries, and will involve […]

Preclinical data published on AM-Pharma’s recAP to treat ultra rare disease Hypophosphatasia

recAP shown to improve skeletal and dental mineralisation in potentially new indication with high unmet medical need. Bunnik, The Netherlands, 2 December 2014. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, today announces that preclinical data on its drug candidate recAP, to treat the ultra […]

AM-Pharma presents preclinical data on mode-of-action for recAP in Acute Kidney Injury

Data shows recAP to increase glomerular filtration rate and creatine clearance Bunnik, The Netherlands, 13 November 2014. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, today presents further preclinical data on its drug candidate recAP, at the American Society of Nephrology (ASN) meeting Kidney Week […]